采用GastroPlus预测PK曲线或PK参数的应用文章 （2011—2020）
导 读
凡默谷技术部精取了2011-2020年10月采用GastroPlus预测PK曲线或PK参数的应用文章70篇。
其中序号1-17的文章是2019年8月-2020年10月新增文章。
希望对您的业务或专业学习有所帮助。内容如下：
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A, Pepin X, Aarons L, Wang Y, Darwich AS, Wood JM, et al. Eur J Pharm Biopharm. Volume 156, November 2020, Pages 50-63. IF= 4.604
2. 使用液相色谱-四极杆飞行时间质谱法测定大鼠血浆中的carisbamate，并使用生理药代动力学PBPK模型预测其人体PK
Qualification and application of liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of carisbamate in rat plasma and prediction of its human pharmacokinetics using physiologically based pharmacokinetic modeling.
A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies.
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades.
In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385.
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats.
Gender effect on the pharmacokinetics of thymoquinone: Preclinical investigation and in silico modeling in male and female rats.
Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using In Silico Tools.
Changes in murine respiratory dynamics induced by aerosolized carfentanil inhalation: efficacy of naloxone and naltrexone.
Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy.
Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model.
A Randomized, Open‐Label, Crossover Phase 1 Study to Evaluate the Effects of Food on the Pharmacokinetics of a Single Oral Dose of a 15‐mg Tylerdipine Tablet in Healthy Chinese Male Volunteers.
Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling.
Prediction of ticagrelor and its active metabolite in liver cirrhosis populations using a physiologically based pharmacokinetic model involving pharmacodynamics.
Integration of Precipitation Kinetics From an In vitro, Multicompartment Transfer System and Mechanistic Oral Absorption Modeling for Pharmacokinetic Prediction of Weakly Basic Drugs.
Application of a Dynamic Fluid & pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus™.
Hens B, Bolger MB. J Pharm Sci. January 2019 Volume 108, Issue 1, Pages 305–315. IF=3.616
23. 一种新型选择性ERα共价拮抗剂（SERCA），H3B-6545的非临床药代动力学和体外代谢
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Rioux N, Smith S, Korpal M, O’Shea M, Prajapati S, Warmuth M, Smith PG. Cancer Chemotherapy and Pharmacology. November 2018. pp 1–10. IF=2.967
24. 受溶酶体捕获的药物（如右美沙芬），其制剂处方的标准制定与体外溶出不相关
The Irrelevance of in vitro Dissolution in Setting Product Specifications for Drugs like Dextromethorphan that are Subject to Lysosomal Trapping.
Bolger MB, Macwan J, Sarfraz M, Almukainzi M, Löbenberg R. J Pharm Sci.Volume 108, Issue 1, January 2019, Pages 268-278. IF=3.616
25. 使用生理药代动力学PBPK模型评估的结构和药代动力学性质相似的化合物
Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
Ellison CA. Regul Toxicol Pharmacol. 2018 Sep 8;99:61-77. IF=2.652
26. 基于hPEPT1绝对表达量建立伐昔洛韦的生理药代动力学PBPK模型及其应用
A physiologically based pharmacokinetic model for valacyclovir established based on absolute expression quantity of hPEPT1 and its application.
Sun L, Wang C, Zhang Y. Eur J Pharm Sci. 2018 Oct 15;123:560-568. IF=3.616
27. 根据碱性盐形药物在胃酸过少或胃酸缺乏的生物相关介质中数据，建立其基于生理学的吸收模型
Physiologically Based Absorption Modeling of Salts of Weak Bases Based on Data in Hypochlorhydric and Achlorhydric Biorelevant Media.
Kesisoglou F, Vertzoni M, Reppas C. AAPS PharmSciTech. 2018 Jun 5. IF=2.401
28. 一种新型口服抗癌药物的药代动力学和种属间放大
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug.
SHetA2. Sharma A, Benbrook MD, Woo S. PLoS One. 2018 Apr 10;13(4): e0194046.IF=2.74
29. 肌氨酸在大鼠中的绝对口服生物利用度：揭开神话的面纱
Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth.
Alraddadi EA, Lillico R, Vennerstrom JL, Lakowski TM, Miller DW. Pharmaceutics.2018 Mar 8;10(1). pii: E31.IF=4.421
30. 在辛伐他汀载药的自微乳化药物递送系统开发中的体外/计算机模拟方法
In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems.
Ćetković Z, Cvijić S, Vasiljević D. Drug Dev Ind Pharm. 2018 May;44(5):849-860.IF=2.365
31. 在先导化合物优化阶段中的生理药代动力学PBPK模型II：通过全局敏感性分析确认影响生物利用度的性质，从而进行基于生物利用度的合理药物设计
Physiologically-Based Pharmacokinetic Modeling in Lead Optimization II: “Rational Bioavailability Design” by Global Sensitivity Analysis to Identify Properties Affecting Bioavailability.
Daga PR, Bolger MB, Haworth IS, Clark RD, Martin EJ. Pharmaceutics, 2018, 15 (3), pp 831–839. IF=4.421
32. 在先导化合物优化阶段中的生理药代动力学PBPK模型I：评估GastroPlus在预测系列化合物生物利用度的准确性和适应性
Physiologically-Based Pharmacokinetic Modeling in Lead Optimization I: Evaluation and Adaptation of GastroPlus to Predict Bioavailability of Medchem Series.
Daga PR, Bolger MBHaworth IS, Clark RD, Martin EJ. Pharmaceutics, 2018, 15 (3), pp 821–830. IF=4.421
33. Ribociclib的生物利用度不受胃pH变化或食物摄入的影响：通过计算机预测In Silico和临床试验进行评估
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Samant TS, Dhuria S, Lu Y, Laisney M, Yang S, Grandeury A,et,al. Clin Pharmacol Ther. 2017 Nov 14.IF=6.565
34. 采用定量药理学的方法进行药物诱发的致心律失常的风险评估：生理药代动力学PBPK模型
Quantitative Systems Pharmacology Approach for Risk Assessment on Drug-Induced Proarrhythmic Effects with Physiologically Based Pharmacokinetic Model.
Nakamura M, Yoneyama F, Hirata A, Fujishima K, Saito R. J Pharmacol Toxicol.Volume 88, Part 2, November–December 2017, Page 183.IF=2.252
35. 用静态和PBPK模型预测氯沙坦给药后,氯沙坦-活性的羧酸代谢物在体内的暴露
Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
Nguyen H Q, Lin J, Kimoto E, et al. J Pharm Sci. 2017. IF=3.616
36. 开发具有非典型分布行为的药物的PBPK模型及资质：以地昔帕明为例
Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: A desipramine case study.
Samant T S, Lukacova V, Schmidt S. CPT: Pharmacometrics & Systems Pharmacology, 2017.CiteScore=5.2
37. 针对生物药剂学数据管理系统中匿名数据的共享和内容管理：首次用于欧盟口服生物药剂学工具orbito IMI项目
Biopharmaceutics data management system for anonymised data sharing and curation: First application with orbito IMI project.
Lacy-Jones K, Hayward P, Andrews S, et al. Computer Methods and Programs in Biomedicine, 2017, 140: 29-44. IF=3.632
38. 使用生理药代动力学PBPK模型设计卡维地洛载药的丝纤蛋白纳米粒子的计算机预测In silico-体外-体内研究
In silico-in vitro-in vivo studies of experimentally designed carvedilol loaded silk fibroincasein nanoparticles using physiological based pharmacokinetic model.
Kumar S, Singh S K. International journal of biological macromolecules, 2017, 96: 403-420. IF=5.162
39. 使用生理药代动力学PBPK模型和生物药剂学分类BCS交叉预测口服吸收
Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models .
Hansmann S, Darwich A, Margolskee A, et al. Journal of Pharmacy and Pharmacology, 2016, 68(12): 1501-1515. IF=2.571
40. 采用高级房室吸收和转运ACAT模型预测CYP3A / P-gp对药物的非线性肠道吸收的相对重要性
The prediction of the relative importance of CYP3A/P-gp to the non-linear intestinal absorption of drugs by advanced compartmental absorption and transit (ACAT) model.
Takano J, Maeda K, Bolger M B, et al. Drug Metabolism and Disposition, 2016: dmd. 116.070011. IF=3.231
41. 用于预测更昔洛韦及其前药缬更昔洛韦在成人和儿童体内行为的生理药代动力学PBPK模型
A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.
Lukacova V, Goelzer P, Reddy M, et al. AAPS J, 2016, 18(6): 1453-1463. IF=3.737
42. 采用临床微给药剂量研究探索人Nav1.7电压依赖性钠通道的四钟选择性抑制剂，在人体内的药代动力学
Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.
Jones HM, Butt RP, Webster RW, Gurrell I, Dzygiel P, Flanagan N, Fraier D, Hay T, Iavarone LE, Luckwell J, Pearce H, Phipps A, Segelbacher J, Speed B, Beaumont K. (2016). Clin Pharmacokinet. Feb 19. IF=4.604
43. 开发生理药代动力学PBPK/药效学模型，以确定导致恩他卡朋生物利用度低的机理
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Identify Mechanisms Contributing to Entacapone Low Bioavailability.
Alqahtani S, Kaddoumi A. (2015). Biopharm Drug Dispos. Aug 21. IF=1.663
44. 3-deazaneplanocin A（一种潜在的表观遗传抗癌剂）的临床前PK研究，并使用GastroPlus™预测该物质的人体PK
Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™.
Sun F, Lee L, Zhang Z, Wang X, Yu Q, Duan X, Chan E. (2015). Eur J Pharm Sci. Jun 25. IF=3.616
45. 采用生理药代动力学PBPK模型预测双环醇控释制剂在人体的PK
Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.
Wang B, Liu Z, Li D, Yang S, Hu J, Chen H, Sheng L, Li Y. (2015). Eur J Pharm Sci.Jun 24. IF=3.616
46. 基于外推的PBPK模型预测左氧氟沙星在人体中的PK和组织分布
Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.
Zhu L, Zhang Y, Yang J, Wang Y, Zhang J, Zhao Y, Dong W. (2015). Eur J Drug Metab Pharmacokinet. Mar 10. IF=1.913
47. 基于外推PBPK模型预测莫西沙星在腹腔感染人群的体内PK和渗透性
Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model.
Zhu L, Yang J, Zhang Y, Wang Y, Zhang J, Zhao Y, Dong W. (2015). Korean J Physiol Pharmacol. Mar;19(2):99-104. IF=1.805
48. 预测不同制剂的在人和狗中的口服PK：结合生理药代动力学PBPK模型与具有生物相关性溶出方法
Interspecies prediction of oral pharmacokinetics of different formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution.
Wu C, Kou L, Ma P, Gao L, Li B, Li R, Luo C, Shentu J, Hea Z, Sun J. (2015). RSC Adv. 5: 19844. IF=3.119
49. [14C] Cobimetinib（MEK抑制剂）在人体中的吸收，代谢，排泄；及肠道代谢对口服处置的影响
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng A, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser M, Musib L. (2015). Drug Metab Dispos. Oct. 8.IF=3.231
50. 建立阿托伐他汀的生理药代动力学PBPK模型
Establishment of physiologically based pharmacokinetic model of atorvastatin.
Liu J-B, Zhu L-Q, Zhang Y, Yang J-W. (2015). Chinese J Hospital Pharmacy.35(16):1465-1469. IF=0.938
51. 新型天然生物碱Jerantinine B的体外抗癌性质和生物学评价
In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B.
Qazzaz ME, Raja VJ, Lim KH, Kam TS, Lee JB, Gershkovich P, Bradshaw TD. (2015).Cancer Lett. Oct 26. IF=7.36
52. 新MDM2拮抗剂（Idasanutlin）在食蟹猴体内的自身诱导作用及该诱导与人体相关性的研究
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ, Yu LJ, Reddy MB, Fretland AJ, Parrott N, Hussain S, Palacios M, Vazvaei F, Zhi J, Tuerck D. (2015). Xenobiotica. Nov 19:1-10. IF=1.902
53. 一种新型的PDE5抑制剂TPN729MA的临床前PK，并使用PBPK模型预测其人体PK
Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.
Gao ZW Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, Chen XY, Li XN, Zhong DF. (2015).Acta Pharmacol Sin. Dec;36(12):1528-36. IF=5.064
54. 采用生理药代动力学PBPK模型，指导溶解度具有pH依赖性的化合物的制剂处方和临床开发
Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility.
Chung J, Alvarez-Nunez F, Chow V, Daurio D, Davis J, Dodds M, Emery M, Litwiler K, Paccaly A, Peng J, Rock B, Wienkers L, Yang C, Yu Z, Wahlstrom J. (2015). J. Pharm. Sci. Jan. 15. IF=3.616
55. 一种用于预防和治疗疟疾的长效二氢乳清酸脱氢酶抑制剂（DSM265）
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, E Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T,et,al. (2015). Sci Transl Med. Jul 15;7(296):296ra111. IF=16.304
56. 21世纪的毒性测试（TT21C）的实施：使用毒性途径进行安全决策并对原型进行风险评估取得的进展
Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
Adeleye Y, Andersen M, Clewell R, Davies M, Dent M, Edwards S, Fowler P, Malcomber S, Nicol B, Scott A, Scott S, Sun B, Westmoreland C, White A, Zhang Q, Carmichael PL. (2014). Toxicology, Feb 25. IF=4.099
57. 使用生理药代动力学PBPK模型对YQA-14的临床前体外和体内ADME性质进行表征并预测在人体内的PK, 这是一种治疗药物成瘾的新多巴胺D3受体拮抗剂候选物
Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically-based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
Liu F, Zhuang X, Yang C, Li Z, Xiong S, Zhang Z, Li J, Lu C, Zhang Z. (2014).Biopharm Drug Dispos. Mar 19. IF=1.663
58. 通过基于生理学的吸收模型预测药物性质对Bitopertin药代动力学的影响
Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin.
Parrott N, Hainzl D, Scheubel E, Krimmer S, Boetsch C, Guerini E, Martin-Facklam M. (2014). AAPS J. Jun. 27. IF=3.737
59. 对乙酰氨基酚在Göttingen小型猪中的PK：通过体内研究和建模阐明决定吸收的生理因素
Pharmacokinetics of Paracetamol in Göttingen Minipigs: In Vivo Studies and Modeling to Elucidate Physiological Determinants of Absorption.
Suenderhauf C, Tuffin G, Lorentsen H, Grimm HP, Flament C, Parrott N. (2014).Pharm Res. May 3. IF=3.242
60. 转化PK / PD模型，并用于评价候选药物的心血管安全性：药物开发中的方法和实例
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
Caruso A, Frances N, Meille C, Greiter-Wilke A, Hillebrecht A, Lave T. (2014). J Pharmacol Toxicol Methods. May 28. IF=2.252
61. 对比格犬肠壁和肝脏中CYP450介导的代谢进行体外-体内转化和基于生理学的建模
In vitro to in vivo extrapolation and physiologically based modeling of cytochrome P450 mediated metabolism in beagle dog gut wall and liver.
Heikkinen AT, Fowler S, Gray L, Li J, Peng Y, Yadava P, Railkar A, Parrott N. (2013).Mol Pharm. Feb. 25. IF=4.321
62. 靶标介导的药物处置模型在小分子热休克蛋白90抑制剂中的应用
Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors.
Yamazaki S, Shen Z, Jiang Y, Smith BJ, Vicini P. (2013) Drug Metab Dispos. Apr 4.IF=3.231
63. 采用生理药代动力学PBPK模型预测Bitopertin的单剂量给药和多剂量给药后的人体PK
Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin.
Parrott N, Hainzl D, Alberati D, Hofmann C, Robson R, Boutouyrie B, Martin-Facklam M. (2013). Clin Pharmacokinet. Apr 17. IF=4.604
64. 通过研究HIV-1附着抑制剂磷酸酯前药的房室吸收模型和吸收部位，来确定开发成缓释制剂的可行性
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.
Brown J, Chien C, Timmins P, Dennis A, Doll W, Sandefer E, Page R, Nettles RE, Zhu L, Grasela D. (2013) J Pharm Sci. 102(6):1742-51. IF=3.616
65. 对UK-343,664的非线性吸收进行计算机建模：它是P-gp和CYP3A4的底物
In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate.
Abuasal BS, Bolger MB, Walker DK, Kaddoumi A. (2012). Mol. Pharm. Feb. 2.IF=4.321
66. 用于预测Patupilone的人体PK的新生理药代动力学PBPK模型
Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B, Heimbach T, Lin T, He H, Wang Y, Tan E. (2012). Cancer Chemotherapy and Pharmacology. 69(4). IF=2.967
67. 评估磷脂酰肌醇3-激酶/哺乳动物雷帕霉素抑制剂GDC-0980的临床前吸收和处置，并预测在人体内的PK和药效
Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human.
Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X. (2012). Drug Metab. Dispos. 40(9):1785-96. IF=3.231
68. 用PBPK模型预测CYP3A底物在人肠道中的代谢-采用GastroPlus™进行评估和应用案例
Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™.
Heikkinen AT, Baneyx G, Caruso A, Parrott N. (2012). Eur. J. Pharm. Sci. 47(2):375-86. IF=3.616
69. 非甾体孕酮受体拮抗剂PF-02413873的临床前和临床PK
Pre-clinical and clinical pharmacokinetics of PF-02413873, a non-steroidal progesterone receptor antagonist.
Bungay PJ, Tweedy S, Howe DC, Gibson KR, Jones HM, Mount NM. (2011). Drug Metab Dispos. May 4. IF=3.231
70. 通过生理药代动力学PBPK模型理解UK-369,003的临床药代动力学